eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2024
vol. 26
 
Share:
Send email
Share:
Original paper

Comparison of remission rates in Egyptian patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors below the age of fifty

Mohamed Said Abd Elwahab
1
,
Nermein Sayed Abd Elaziz
1
,
Nehad Mohamed Tawfeek
1
,
Moataz Fathy Mohamed
1
,
Ibrahem Ahmed Ibrahem
1

  1. Internal Medicine Department, Faculty of Medicine Cairo University, Cairo, Egypt
Family Medicine & Primary Care Review 2024; 26(3): 299–302
DOI: https://doi.org/10.5114/fmpcr.2024.142554
Online publish date: 2024/09/30
Article file
- 04 FM&PCR 3 24 - O - Elwahab - 1604 - Comparison.pdf  [0.46 MB]
Get citation
 
PlumX metrics:
 
1. García-Gutiérrez V, Breccia M, Jabbour E, et al. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol 2022; 15(1): 90, doi: 10.1186/s13045-022-01309-0.
2. Lin Q, Mao L, Shao L, et al. Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Front Oncol 2020; 10: 580759.
3. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34(4): 966–984.
4. Vener C, Banzi R, Ambrogi F, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 2020; 4(12): 2723–2735, doi: 10.1182/bloodadvances.2019001329.
5. Rosti G, Castagnetti F, Gugliotta G, et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol 2017; 14: 141–154, doi: 10.1038/nrclinonc.2016.139.
6. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 2020; 95(6): 691–709.
7. Umezawa Y, Sasaki K. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol 2023; 117(1): 24–29.
8. Haguet H, Bouvy C, Delvigne A-S, et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front Pharmacol 2020; 11: 1007.
9. Haguet H, Douxfils J, Chatelain C, et al. BCR-ABL tyrosine kinase inhibitors: which mechanism (s) may explain the risk of thrombosis? TH Open 2018; 2(1): e68–e88.
10. Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 2017; 16(1): 5–12.
11. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021; 35(2): 440–453.
12. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2251–2259.
13. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12(9): 841–851.
14. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123(9): 1353–1360.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.